Symbols / PLX $2.09 -2.34% Protalix BioTherapeutics, Inc.

Healthcare • Biotechnology • United States • ASE
PLX Chart
About

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 168.39M
Enterprise Value 146.44M Income -6.60M Sales 52.74M
Book/sh 0.60 Cash/sh 0.38 Dividend Yield —
Payout 0.00% Employees 226 IPO —
P/E 26.75 Forward P/E 3.37 PEG —
P/S 3.19 P/B 3.48 P/C —
EV/EBITDA -36.29 EV/Sales 2.78 Quick Ratio 1.50
Current Ratio 2.51 Debt/Eq 17.25 LT Debt/Eq —
EPS (ttm) -0.08 EPS next Y 0.62 EPS Growth —
Revenue Growth -49.90% Earnings 2026-05-08 ROA -4.41%
ROE -14.44% ROIC — Gross Margin 13.01%
Oper. Margin -51.06% Profit Margin -12.52% Shs Outstand 80.57M
Shs Float 67.43M Short Float 5.67% Short Ratio 3.80
Short Interest — 52W High 3.19 52W Low 1.32
Beta -0.23 Avg Volume 1.27M Volume 1.02M
Target Price $11.00 Recom Strong_buy Prev Close $2.14
Price $2.09 Change -2.34%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.00
Mean price target
2. Current target
$2.09
Latest analyst target
3. DCF / Fair value
$-2.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.09
Low
$10.00
High
$12.00
Mean
$11.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-19 reit HC Wainwright & Co. Buy → Buy $12
2025-11-21 main HC Wainwright & Co. Buy → Buy $12
2025-02-03 main HC Wainwright & Co. Buy → Buy $15
2023-11-14 reit HC Wainwright & Co. Buy → Buy $10
2023-10-31 main HC Wainwright & Co. Buy → Buy $10
News
RSS: Latest PLX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-19 BASHAN DROR Chief Executive Officer — 56,000 $1.81 $101,360
2025-11-18 BAR SHALEV AMOS Director — 168 $1.87 $314
2025-09-03 MELINCOFF GWEN A Director — 7,500 $0.00 $0
2025-09-03 BAR SHALEV AMOS Director — 7,500 $0.00 $0
2025-09-03 BOUDES POL F Director — 7,500 $0.00 $0
2025-09-03 SCHWARTZ AHARON Director — 7,500 $0.00 $0
2025-09-03 NAOS YARON Officer — 25,000 $0.00 $0
2025-09-03 BASHAN DROR Chief Executive Officer — 195,000 $0.00 $0
2025-09-03 FORSTER ELIOT Director — 7,500 $0.00 $0
2025-09-03 BEN ZVI SHMUEL Director — 7,500 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
53.40
-18.47%
65.49
+37.48%
47.64
+24.22%
38.35
Operating Revenue
53.40
-18.47%
65.49
+37.48%
47.64
+24.22%
38.35
Cost Of Revenue
24.32
+5.82%
22.98
+17.30%
19.59
+19.84%
16.35
Reconciled Cost Of Revenue
24.32
+5.82%
22.98
+17.30%
19.59
+19.84%
16.35
Gross Profit
29.08
-31.60%
42.51
+51.58%
28.05
+27.48%
22.00
Operating Expense
25.16
-21.49%
32.05
-21.94%
41.06
-3.30%
42.46
Research And Development
12.97
-24.12%
17.09
-41.76%
29.35
-1.29%
29.73
Selling General And Administration
12.19
-18.49%
14.96
+27.73%
11.71
-8.00%
12.73
Total Expenses
49.48
-10.09%
55.03
-9.26%
60.65
+3.13%
58.81
Operating Income
3.92
-62.55%
10.46
+180.37%
-13.01
+36.40%
-20.46
Total Operating Income As Reported
3.92
-62.55%
10.46
+180.37%
-13.01
+36.40%
-20.46
EBITDA
6.52
-49.60%
12.94
+219.99%
-10.78
+43.08%
-18.94
Normalized EBITDA
6.52
-49.60%
12.94
+219.99%
-10.78
+43.08%
-18.94
Reconciled Depreciation
1.30
+9.49%
1.19
+9.67%
1.09
-2.86%
1.12
EBIT
5.22
-55.59%
11.75
+198.97%
-11.87
+40.84%
-20.06
Net Income
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Pretax Income
4.15
-51.51%
8.57
+159.50%
-14.40
+47.80%
-27.58
Net Non Operating Interest Income Expense
0.24
+112.51%
-1.89
-36.95%
-1.38
+80.58%
-7.12
Interest Expense Non Operating
1.06
-66.60%
3.18
+25.74%
2.53
-66.37%
7.52
Net Interest Income
0.24
+112.51%
-1.89
-36.95%
-1.38
+80.58%
-7.12
Interest Expense
1.06
-66.60%
3.18
+25.74%
2.53
-66.37%
7.52
Interest Income Non Operating
1.30
+1.01%
1.29
+12.22%
1.15
+185.79%
0.40
Interest Income
1.30
+1.01%
1.29
+12.22%
1.15
+185.79%
0.40
Tax Provision
1.22
+381.10%
0.25
-52.08%
0.53
0.00
Tax Rate For Calcs
0.00
+892.09%
0.00
-25.87%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Net Income From Continuing Operation Net Minority Interest
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Net Income From Continuing And Discontinued Operation
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Net Income Continuous Operations
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Normalized Income
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Net Income Common Stockholders
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Diluted EPS
0.04
-55.56%
0.09
+129.03%
-0.31
+50.00%
-0.62
Basic EPS
0.04
-66.67%
0.12
+138.71%
-0.31
+50.00%
-0.62
Basic Average Shares
72.53
+7.43%
67.51
+39.28%
48.47
+9.81%
44.14
Diluted Average Shares
81.06
-1.66%
82.42
+70.04%
48.47
+9.81%
44.14
Diluted NI Availto Com Stockholders
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Line Item Trend 2023-12-31
Total Assets
84.43
Current Assets
69.93
Cash Cash Equivalents And Short Term Investments
44.56
Cash And Cash Equivalents
23.63
Other Short Term Investments
20.93
Receivables
5.27
Accounts Receivable
5.27
Inventory
19.05
Raw Materials
4.18
Work In Process
9.05
Finished Goods
5.81
Prepaid Assets
0.44
Restricted Cash
—
Other Current Assets
0.61
Total Non Current Assets
14.50
Net PPE
10.88
Gross PPE
45.57
Accumulated Depreciation
-34.69
Properties
0.00
Machinery Furniture Equipment
3.08
Other Properties
24.84
Leases
17.64
Non Current Deferred Assets
3.09
Non Current Deferred Taxes Assets
3.09
Total Liabilities Net Minority Interest
50.87
Current Liabilities
45.53
Payables And Accrued Expenses
22.27
Payables
7.83
Accounts Payable
4.32
Other Payable
0.64
Current Accrued Expenses
14.43
Employee Benefits
0.71
Pensionand Other Post Retirement Benefit Plans Current
1.60
Total Tax Payable
2.88
Income Tax Payable
2.88
Current Debt And Capital Lease Obligation
21.66
Current Debt
20.25
Other Current Borrowings
20.25
Current Capital Lease Obligation
1.41
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Total Non Current Liabilities Net Minority Interest
5.33
Long Term Debt And Capital Lease Obligation
4.62
Long Term Debt
—
Long Term Capital Lease Obligation
4.62
Defined Pension Benefit
0.53
Non Current Pension And Other Postretirement Benefit Plans
0.71
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Stockholders Equity
33.57
Common Stock Equity
33.57
Capital Stock
0.07
Common Stock
0.07
Share Issued
72.95
Ordinary Shares Number
72.95
Treasury Shares Number
0.00
Additional Paid In Capital
415.05
Retained Earnings
-381.55
Total Equity Gross Minority Interest
33.57
Total Capitalization
33.57
Working Capital
24.40
Invested Capital
53.82
Total Debt
26.28
Net Debt
—
Capital Lease Obligations
6.03
Net Tangible Assets
33.57
Tangible Book Value
33.57
Current Notes Payable
—
Current Provisions
—
Interest Payable
0.51
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
8.67
+758.12%
-1.32
+94.73%
-25.00
-143.07%
-10.29
Cash Flow From Continuing Operating Activities
8.67
+758.12%
-1.32
+94.73%
-25.00
-143.07%
-10.29
Net Income From Continuing Operations
2.93
-64.73%
8.31
+155.68%
-14.93
+45.88%
-27.58
Depreciation Amortization Depletion
1.30
+9.49%
1.19
+9.67%
1.09
-2.86%
1.12
Depreciation
1.30
+9.49%
1.19
+9.67%
1.09
-2.86%
1.12
Depreciation And Amortization
1.30
+9.49%
1.19
+9.67%
1.09
-2.86%
1.12
Other Non Cash Items
0.31
+151.67%
-0.60
+12.92%
-0.69
-122.30%
3.09
Pension And Employee Benefit Expense
-0.17
-259.57%
-0.05
+91.30%
-0.54
-1736.36%
0.03
Stock Based Compensation
3.25
-5.66%
3.45
+65.37%
2.08
-12.21%
2.38
Deferred Tax
0.24
+107.63%
-3.09
0.00
0.00
Deferred Income Tax
0.24
+107.63%
-3.09
0.00
0.00
Operating Gains Losses
-0.17
-352.63%
-0.04
+92.96%
-0.54
-166.42%
0.81
Gain Loss On Sale Of PPE
-0.00
-133.33%
0.01
0.00
+100.00%
-0.05
Change In Working Capital
0.81
+107.70%
-10.54
+12.28%
-12.02
-221.35%
9.90
Change In Receivables
2.32
+641.36%
-0.43
+64.15%
-1.19
-15.70%
-1.03
Changes In Account Receivables
2.32
+641.36%
-0.43
+64.15%
-1.19
-15.70%
-1.03
Change In Inventory
-2.20
+1.92%
-2.24
-294.87%
1.15
+123.60%
-4.87
Change In Payables And Accrued Expense
0.70
-86.86%
5.29
+210.22%
-4.80
-301.43%
2.38
Change In Other Working Capital
—
-13.18
-84.00%
-7.16
-154.13%
13.23
Change In Other Current Assets
-0.00
-130.77%
0.01
+360.00%
-0.01
-102.07%
0.24
Change In Other Current Liabilities
—
0.00
0.00
+100.00%
-0.05
Investing Cash Flow
4.22
+125.26%
-16.71
-231.90%
-5.04
-126.61%
18.92
Cash Flow From Continuing Investing Activities
4.22
+125.26%
-16.71
-231.90%
-5.04
-126.61%
18.92
Net PPE Purchase And Sale
-1.28
-11.31%
-1.15
-82.96%
-0.63
+55.33%
-1.41
Purchase Of PPE
-1.28
-11.58%
-1.15
-82.96%
-0.63
+56.96%
-1.46
Sale Of PPE
0.00
0.00
0.00
-100.00%
0.05
Capital Expenditure
-1.28
-11.58%
-1.15
-82.96%
-0.63
+56.96%
-1.46
Net Investment Purchase And Sale
5.42
+135.15%
-15.42
-208.40%
-5.00
-125.00%
20.00
Purchase Of Investment
-15.00
+26.54%
-20.42
-27.63%
-16.00
+57.71%
-37.84
Sale Of Investment
20.42
+308.40%
5.00
-54.55%
11.00
-80.98%
57.84
Net Other Investing Changes
0.08
+156.34%
-0.14
-123.95%
0.59
+81.35%
0.33
Financing Cash Flow
-16.79
-168.09%
24.67
+199.42%
8.24
-31.79%
12.08
Cash Flow From Continuing Financing Activities
-16.79
-168.09%
24.67
+199.42%
8.24
-31.79%
12.08
Net Issuance Payments Of Debt
-20.42
0.00
0.00
+100.00%
-34.12
Repayment Of Debt
-20.42
0.00
0.00
+100.00%
-34.12
Long Term Debt Payments
—
0.00
0.00
+100.00%
-34.12
Net Long Term Debt Issuance
—
0.00
0.00
+100.00%
-34.12
Short Term Debt Payments
-20.42
0.00
0.00
—
Net Short Term Debt Issuance
-20.42
0.00
0.00
—
Net Common Stock Issuance
3.63
-84.86%
23.95
+190.85%
8.24
-82.17%
46.20
Proceeds From Stock Option Exercised
0.00
-100.00%
0.71
+35500.00%
0.00
0.00
Changes In Cash
-3.90
-158.75%
6.64
+130.45%
-21.80
-205.23%
20.71
Effect Of Exchange Rate Changes
0.03
+121.93%
-0.11
-48.05%
-0.08
-1383.33%
0.01
Beginning Cash Position
23.63
+38.12%
17.11
-56.11%
38.98
+113.44%
18.27
End Cash Position
19.76
-16.39%
23.63
+38.12%
17.11
-56.11%
38.98
Free Cash Flow
7.39
+399.64%
-2.47
+90.37%
-25.63
-118.22%
-11.74
Interest Paid Supplemental Data
—
—
—
3.41
Common Stock Issuance
3.63
-84.86%
23.95
+190.85%
8.24
-82.17%
46.20
Issuance Of Capital Stock
3.63
-84.86%
23.95
+190.85%
8.24
-82.17%
46.20
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category